1)Ohashi Y, Ebihara N, Fujishima H et al:A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther 26:165-174, 2010
2)Ebihara N, Ohashi Y, Uchio E et al:A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 25:365-372, 2009
3)Shimura M, Yasuda K, Miyazawa A et al:Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis. Am J Ophthalmol 151:697-702, 2010
4)Lambiase A, Bonini S, Rasi G et al:Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma. Arch Ophthalmol 121:615-620, 2003
5)Galli SJ, Tsai M, Piliponsky AM:The development of allergic inflammation. Nature 454:445-454, 2008
6)Corren J, Lemanske RF, Hanania NA et al:Lebrikizumab treatment in adults with asthma. N Engl J Med 365:1088-1098, 2011
7)Cox LS, Larenas Linnemann D, Nolte H et al:Sublingual immunotherapy:a comprehensive review. J Allergy Clin Immunol 117:1021-1035, 2006
8)Allen JE, Maizels RM:Diversity and dialogue in immunity to helminths. Nat Rev Immunol 11:375-388, 2011
9)Locksley RM:Asthma and allergic inflammation. Cell 140:777-783, 2010
10)Oliphant CJ, Barlow JL, McKenzie AN:Insights into the initiation of type 2 immune responses. Immunology 134:378-385, 2011
11)Matsuda A, Ebihara N, Yokoi N et al:Functional role of thymic stromal lymphopoietin in chronic allergic keratoconjunctivitis. Invest Ophthalmol Vis Sci 51:151-155, 2010
12)Matsuda A, Okayama Y, Terai N et al:The role of interleukin-33 in chronic allergic conjunctivitis. Invest Ophthalmol Vis Sci 50:4646-4652, 2009